Related references
Note: Only part of the references are listed.Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
Yoshiya Tanaka et al.
RMD OPEN (2021)
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2020)
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension
Ronald F. van Vollenhoven et al.
RHEUMATOLOGY (2020)
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
Alexis Mathian et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus
Ippei Miyagawa et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
State-of-the-art treatment of systemic lupus erythematosus
Yoshiya Tanaka
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting
Mariele Gatto et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina
A. Babini et al.
LUPUS (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2019)
High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene
M. Marin-Rosales et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2019)
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
Daniel J. Wallace et al.
ARTHRITIS & RHEUMATOLOGY (2019)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment
Vibeke Strand et al.
ARTHRITIS CARE & RESEARCH (2019)
Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes
J. P. Suso et al.
LUPUS (2018)
Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men
A. Schwarting et al.
LUPUS (2018)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Luca Iaccarino et al.
JOURNAL OF AUTOIMMUNITY (2018)
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis
Eli M. Miloslavsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus
Luca Iaccarino et al.
ARTHRITIS CARE & RESEARCH (2017)
BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis
SunAh Kang et al.
JOURNAL OF IMMUNOLOGY (2017)
Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
I. N. Bruce et al.
LUPUS (2016)
Systemic lupus erythematosus
Arvind Kaul et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
C. E. Collins et al.
LUPUS SCIENCE & MEDICINE (2016)
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
Joyce S. Hui-Yuen et al.
JOURNAL OF RHEUMATOLOGY (2015)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The Characteristics and Significance of Locally Infiltrating B Cells in Lupus Nephritis and Their Association with Local BAFF Expression
Chuan-Yin Sun et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2012)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort
M. B. Urowitz et al.
ARTHRITIS CARE & RESEARCH (2012)
Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients
L. D. Zhao et al.
LUPUS (2010)
Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals
Stanley Xu et al.
VALUE IN HEALTH (2010)
Growth mixture modeling: A method for identifying differences in longitudinal change among unobserved groups
Nilam Ram et al.
INTERNATIONAL JOURNAL OF BEHAVIORAL DEVELOPMENT (2009)
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2008)
Combined oral contraceptives in women with systemic lupus erythematosus
M Petri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
